Clinical Trials
15 trialsNCT07379125 2026-05-22
Therapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Phase 1 Recruiting
NCT07469891 2026-05-14
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Phase 1 Recruiting
NCT06313593 2026-05-04
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT06034002 2026-04-17
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT07441694 2026-04-15
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT07008118 2026-04-06
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT04024761 2026-04-03
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07020533 2026-03-27
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT05936359 2026-03-24
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT03630991 2026-03-02
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05549661 2026-02-23
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Mayo Clinic
Phase 1 Recruiting
NCT06138587 2026-01-02
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06291987 2025-11-05
MPN
University of Chicago
Phase 1 Recruiting
NCT05423691 2025-04-13
TREG108
Cellenkos, Inc.
Phase 1 Recruiting
NCT06218628 2024-05-03
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
Phase 1 Recruiting